DexCom (NASDAQ:DXCM) PT Raised to $151.00

DexCom (NASDAQ:DXCM – Get Free Report) had its target price raised by equities research analysts at Raymond James from $147.00 to $151.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “strong-buy” rating on the medical device company’s stock. Raymond James’ target price would indicate a potential upside of 18.51% […]

Leave a Reply

Your email address will not be published.

Previous post Needham & Company LLC Trims Cara Therapeutics (NASDAQ:CARA) Target Price to $5.00
Next post Needham & Company LLC Increases Viant Technology (NASDAQ:DSP) Price Target to $10.00